Vaccines and the Infectious Diseases They Prevent

Image representing the teeth of a bat with IMOVAX RABIES and IMOGRAM RABIES-HT writen below

Characteristics of IMOVAX Rabies vaccine

IMOVAX Rabies vaccine is a sterile, stable, freeze-dried suspension of rabies virus^1,2

IMOVAX Rabies vaccine is grown in MRC-5 human diploid cell line, concentrated by ultrafiltration, and inactivated by beta-propiolactone^1,2

One dose of reconstituted IMOVAX Rabies vaccine contains less than 100 mg albumin, less than 150 µg of neomycin sulfate, and 20 µg of phenol red indicator¹

IMOVAX Rabies vaccine contains no preservative or stabilizer. It should be used immediately after reconstitution; if not administered promptly, it should be discarded.¹

The potency of one dose (1.0 mL) of IMOVAX Rabies vaccine is equal to or greater than 2.5 international units of rabies antigen, which is the World Health Organization (WHO) recommended standard for protection^1-3

View full Prescribing Information for IMOVAX Rabies vaccine.

References: 1. IMOVAX Rabies Vaccine Prescribing Information, December 2005. 2. Centers for Disease Control and Prevention (CDC). Human rabies prevention—United States, 1999: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1999;48:1-21. 3. WHO Expert Committee on Rabies: sixth report. World Health Organ Tech Rep Ser. 1973;523:1-55.

IMOVAX® Rabies

Indication

IMOVAX Rabies vaccine is indicated for active, pre- and post-exposure immunization against rabies.

Safety Information
The most common local and systemic adverse reactions to IMOVAX Rabies vaccine may include injection site pain, erythema, and swelling; headache, nausea, and muscle aches. Other adverse reactions may occur. Once initiated for post-exposure treatment rabies vaccination should not be interrupted or discontinued because of mild local or systemic adverse reactions. Usually such reactions can be successfully managed with anti-inflammatory and antipyretic agents. Vaccination with IMOVAX Rabies vaccine may not protect all individuals.

Before administering IMOVAX Rabies vaccine, please see accompanying full Prescribing Information.

IMOGAM® Rabies–HT

Indication
IMOGAM Rabies-HT immune globulin is given for passive immunization of individuals suspected of exposure to rabies.

Safety Information
Side effects to the IMOGAM Rabies-HT immune globulin include injection site tenderness, pain, and muscle soreness or stiffness. Other side effects may occur. IMOGAM Rabies-HT immune globulin should not be given in repeated doses once vaccine treatment has begun. IMOGAM Rabies-HT immune globulin is made from components of human blood and, therefore, this vaccine may carry a risk of transmitting infectious material, although careful selection of donors and extensive testing are intended to minimize this risk. Treatment with a rabies immune globulin may not protect all individuals.

For more information about IMOGAM Rabies-HT immune globulin, talk to your health-care professional.

Last modified: 5/2/08